Drug intelligence / Profile preview

live attenuated varicella vaccine

Development stage: Unknown
Lead developer: Shanghai Municipal Center for Disease Control and Prevention
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

A live attenuated vaccine used for the prevention of varicella (chickenpox) in children. It contains a weakened form of the varicella-zoster virus (VZV) to stimulate a protective immune response. This specific vaccine is being evaluated by the Shanghai Municipal Center for Disease Control and Prevention in a Phase 4 study to determine the optimal interval for a two-dose regimen (ranging from 3 months to 5 years) and to assess the safety and immunogenicity when co-administered with the MMR vaccine. The vaccine works by inducing both humoral and cell-mediated immune responses against VZV.

Other names: varicella vaccinechickenpox vaccine

Beyond the preview

Go deeper on live attenuated varicella vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on live attenuated varicella vaccine.

Explore the full profile